eTheRNA immunotherapies and Ghent University Announce mRNA Delivery Collaboration and License Agreement

eTheRNA immunotherapies and Ghent University…

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir’s COVID-19 antibody candidate neutralizes…

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Immunic, Inc. Announces FDA Clearance…

eTheRNA immunotherapies and Quantoom Biosciences Announce a Strategic Collaboration for the Development of a Novel RNA Production System

eTheRNA immunotherapies and Quantoom Biosciences…

eTheRNA and VUB expand strategic collaboration to engineer next generation mRNA therapeutics with TetraMix®

eTheRNA and VUB expand strategic…

Novadip Biosciences reports positive data from phase I study of NVD-001 for spinal fusion

Novadip Biosciences reports positive data…

Confo Therapeutics Establishes Medical Advisory Board

Confo Therapeutics Establishes Medical Advisory…

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

Minoryx publishes mechanism of action…

Indigo Diabetes Appoints Paul Moraviec as Chairman of the Board

Indigo Diabetes Appoints Paul Moraviec…

Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Minoryx Phase 2/3 ‘ADVANCE’ study…